je.st
news
RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
2014-04-30 11:16:46| Biotech - Topix.net
RXI-109 is an sd-rxRNA compound that targets connective tissue growth factor and is being developed for the treatment of abnormal dermal scars, such as hypertrophic scars and keloids, in conjunction with scar or keloid revision surgery.
Tags: study
phase
announces
initiation
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||